Far to the left-field of my normal research, I’m pursuing a new hypothesis: whether there is a connection between
- people who get envenomated by the asp caterpillar, and
- the acquisition of antiphospholipid syndrome (APS)
At first blush, these seem clinically unconnected. The first involves a venomous caterpillar, and the second involves an acquired disorder that increases the chance of stroke or other blood-clotting problems. However, I have a nagging suspicion that the two are related — that is, that the former might lead to the latter. I’ve read every paper on the geographical variations in APS, but so far no study would be capable of addressing this hypothesis. So I’m turning to the net. If you have been envenomated by the asp caterpillar at some point in your life, and if you have a current diagnosis of antiphospholipid syndrome (also known sometimes as antiphospholipid antibody syndrome), please email me to get in touch: APS@eagleman.com. I’m not asking for any detailed patient information from you; for the moment, I simply want to gain a rough estimate of how common the co-occurrence is. Thank you in advance for your help in addressing the origins of this still-mysterious clinical disorder.
"David Eagleman is the kind of guy who really does make being a neuroscientist look like fun."
- New York Times
"What Eagleman seems to be calling for is a new Enlightenment."
- Sunday Herald
"Eagleman has a talent for testing the untestable, for taking seemingly sophomoric notions and using them to nail down the slippery stuff of consciousness."
- The New Yorker
"A popularizer of impressive gusto...[Eagleman] aims, grandly, to do for the study of the mind what Copernicus did for the study of the stars."
- New York Observer
"David Eagleman may be the best combination of scientist and fiction-writer alive."
- Stewart Brand
"David Eagleman offers startling lessons.... His method in both Sum and his new book, Incognito, is to ask us to cast off our lazy, commonplace assumptions."
- The Guardian
"[A] neuroscientist and polymath."
- Wall Street Journal